Loading...
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
The mTOR signaling pathway is dysregulated in ~50% of all human malignancies and is a major cancer drug target. Although rapamycin analogs (rapalogs) have shown clinical efficacy in a subset of cancers, they do not fully exploit the antitumor potential of mTOR targeting. Because the mTOR kinase doma...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3073023/ https://ncbi.nlm.nih.gov/pubmed/21333749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2011.02.008 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|